Company Filing History:
Years Active: 2005-2013
Title: Michael Stephen Brieger: Innovator in HIV Protease Inhibition
Introduction
Michael Stephen Brieger is a notable inventor based in Greenwood, IN (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of inhibitors for aspartyl proteases. With a total of two patents to his name, Brieger's work focuses on combating HIV through innovative chemical compounds.
Latest Patents
Brieger's latest patents include a novel class of sulfonamides that serve as aspartyl protease inhibitors. One of the key inventions relates to HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. These compounds are designed to inhibit the activity of HIV-1 and HIV-2 proteases, making them valuable as anti-viral agents. The patents also encompass methods for screening compounds for anti-HIV activity, showcasing Brieger's commitment to advancing therapeutic options for HIV treatment.
Career Highlights
Michael Stephen Brieger is currently associated with Vertex Pharmaceuticals, Inc., where he continues to contribute to groundbreaking research in the pharmaceutical industry. His work has been instrumental in developing effective treatments for viral infections, particularly those caused by HIV.
Collaborations
Brieger has collaborated with esteemed colleagues, including Michael Robin Hale and Roger D Tung. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to significant advancements in their field.
Conclusion
Michael Stephen Brieger's contributions to the development of HIV protease inhibitors highlight his role as a key innovator in the pharmaceutical industry. His patents and collaborative efforts continue to pave the way for new treatments that can significantly impact public health.